InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 196571

Wednesday, 11/19/2014 9:22:03 AM

Wednesday, November 19, 2014 9:22:03 AM

Post# of 345994
Dmitry Gabrilovich : Peregrine Pharmaceuticals KOL :

CHOP Cell Pathology Seminar: Dmitry Gabrilovich, M.D., Ph.D.
(Seminar)
Calendar: IFI-non-Penn
Date: Wednesday 2/11/2015
2 Month(s) 3 Week(s) 3 Day(s)
Time: 12:00 pm - 1:00 pm
Organizer: Kaitlyn Baraldi ( Kaitlyn Baraldi )
Notes:

Christopher M. Davis Professor
Department of Pathology and Laboratory Medicine
Perelman School of Medicine University of Pennsylvania

http://www.med.upenn.edu/apps/thyme/event_view.php?eid=55658&instance=2015-2-11

http://www.med.upenn.edu/apps/thyme/index.php


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News